1. Prospective Head-to-Head Comparison of 18 F-PSMA PET/CT and 18 F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
- Author
-
Madsen C, Fuglø D, Pedersen M, Broholm R, Østergren PB, Bisbjerg R, Kongsted P, Nielsen K, Haarmark C, and Zacho H
- Subjects
- Humans, Male, Aged, Prospective Studies, Middle Aged, Aged, 80 and over, Edetic Acid analogs & derivatives, Oligopeptides, Risk, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology, Bone Neoplasms secondary, Bone Neoplasms diagnostic imaging, Sodium Fluoride, Fluorine Radioisotopes
- Abstract
Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used for primary staging in prostate cancer (PC), mainly because of its improved accuracy in detecting lymph node metastases compared with conventional imaging. However, the diagnostic benefit of PSMA PET/CT for detecting bone metastases is less well established. This study compares the diagnostic accuracy of
18 F-PSMA PET/CT and18 F-NaF PET/CT for detecting bone metastases in patients newly diagnosed with PC. Methods: This prospective study included patients with histologically confirmed high-risk PC. All participants were referred from the department of urology to18 F-NaF PET/CT and underwent18 F-PSMA PET/CT within 3 weeks. Images were reviewed by 2 nuclear medicine physicians unaware of the results of the other imaging modality. Presence or absence of bone metastases and number of metastatic lesions were recorded. A reference standard was established at the patient level based on agreement between the 2 imaging modalities. In cases of concordance, both modalities were deemed correct. In cases of discordance, additional follow-up scans were performed. Diagnostic performance metrics, including sensitivity, specificity, and accuracy, were calculated. Results: In total, 160 participants were included. Sensitivity, specificity, and accuracy for detecting bone metastases at the patient level were 0.98, 0.99, and 0.99, respectively, for18 F-PSMA PET/CT, and 0.91, 1.00, and 0.97, respectively, for18 F-NaF PET/CT. No significant differences were found. The concordance rate of bone metastases between18 F-NaF and18 F-PSMA PET/CT at the patient level was observed in 154 patients (96.3%).18 F-PSMA PET/CT tended to identify more bone metastases per patient than18 F-NaF PET/CT. Conclusion: Both18 F-NaF and18 F-PSMA PET/CT exhibit high diagnostic accuracy for detecting bone metastases in newly diagnosed high-risk PC patients.18 F-PSMA PET/CT may detect additional metastatic lesions compared with18 F-NaF PET/CT. Subsequent18 F-NaF PET/CT may be redundant if no bone metastases are found on18 F-PSMA PET/CT., (© 2025 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2025
- Full Text
- View/download PDF